TY - JOUR
T1 - Metabolic syndrome and all-cause mortality in older men and women
AU - Forti, Paola
AU - Pirazzoli, Gian L.
AU - Maltoni, Benedetta
AU - Bianchi, Giampaolo
AU - Magalotti, Donatella
AU - Muscari, Antonio
AU - Mariani, Erminia
AU - Ravaglia, Giovanni
AU - Zoli, Marco
PY - 2012/9
Y1 - 2012/9
N2 - Background Prevalence of metabolic syndrome (MetS) increases with age, but its association with all-cause mortality in older persons remains uncertain. This study investigated the association of all-cause mortality with MetS and its individual components in older men and women. Methods A total of 917 men and 1043 women aged 65years and older from two Italian population-based cohorts were included in the study. MetS was defined according to four different definitions: National Cholesterol Education Program (NCEP), NCEP revised according to the American Heart Association and National Heart Lung Blood Institute (NCEP-R), International Diabetes Organization (IDF) and Joint Interim Statement (JIS). All of these definitions include abdominal obesity, hyperglycaemia, hypertriglyceridaemia, low high-density lipoprotein cholesterol and hypertension. Hazard Ratios (HR) and their corresponding 95% confidence interval (95%CI) estimated from multivariable-adjusted Cox regression models were used to investigate the associations of all-cause mortality with baseline MetS status and individual MetS components. Results After 6·5±1·8years of follow-up, there were 179 deaths among women and 193 among men. Mortality risk was increased in women with MetS by any definition, regardless of individual components, but limited to age 70-79years (NCEP, HR=2·02, 95%CI, 1·16-3·53; NCEP-R, HR=2·51, 95%CI, 1·45-4·34; IDF, HR=2·16, 95%CI, 1·26-3·72; JIS, HR=2·16, 95%CI, 1·26-3·72). Mortality risk of men was associated with hypertriglyceridaemia below age 70years (HR=2·50, 95%CI, 1·19-5·25), but unrelated to MetS status. Conclusions Metabolic Syndrome is associated with all-cause mortality in older women but not in men. The association, however, is limited to a narrow age range.
AB - Background Prevalence of metabolic syndrome (MetS) increases with age, but its association with all-cause mortality in older persons remains uncertain. This study investigated the association of all-cause mortality with MetS and its individual components in older men and women. Methods A total of 917 men and 1043 women aged 65years and older from two Italian population-based cohorts were included in the study. MetS was defined according to four different definitions: National Cholesterol Education Program (NCEP), NCEP revised according to the American Heart Association and National Heart Lung Blood Institute (NCEP-R), International Diabetes Organization (IDF) and Joint Interim Statement (JIS). All of these definitions include abdominal obesity, hyperglycaemia, hypertriglyceridaemia, low high-density lipoprotein cholesterol and hypertension. Hazard Ratios (HR) and their corresponding 95% confidence interval (95%CI) estimated from multivariable-adjusted Cox regression models were used to investigate the associations of all-cause mortality with baseline MetS status and individual MetS components. Results After 6·5±1·8years of follow-up, there were 179 deaths among women and 193 among men. Mortality risk was increased in women with MetS by any definition, regardless of individual components, but limited to age 70-79years (NCEP, HR=2·02, 95%CI, 1·16-3·53; NCEP-R, HR=2·51, 95%CI, 1·45-4·34; IDF, HR=2·16, 95%CI, 1·26-3·72; JIS, HR=2·16, 95%CI, 1·26-3·72). Mortality risk of men was associated with hypertriglyceridaemia below age 70years (HR=2·50, 95%CI, 1·19-5·25), but unrelated to MetS status. Conclusions Metabolic Syndrome is associated with all-cause mortality in older women but not in men. The association, however, is limited to a narrow age range.
KW - All-cause mortality
KW - Gender
KW - Longitudinal study
KW - Metabolic syndrome
KW - Older age
KW - Risk factor
UR - http://www.scopus.com/inward/record.url?scp=84865184421&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84865184421&partnerID=8YFLogxK
U2 - 10.1111/j.1365-2362.2012.02688.x
DO - 10.1111/j.1365-2362.2012.02688.x
M3 - Article
C2 - 22591032
AN - SCOPUS:84865184421
VL - 42
SP - 1000
EP - 1009
JO - European Journal of Clinical Investigation
JF - European Journal of Clinical Investigation
SN - 0014-2972
IS - 9
ER -